Skip to main content

Table 2 Univariate and multivariate analyses of LBX2-AS1 expression and patients' survival in the study cohort

From: LncRNA LBX2-AS1 promotes colorectal cancer progression and 5-fluorouracil resistance

Variables Categories Umivariate analysis Multivariate analysis
HR 95%Cl P value HR 95%Cl P value
Overall survival
 Gender Male/female 1.236 0.335 2.397 0.808 NA
 Age (years) ≥ 60/< 60 0.961 0.763 1.861 0.477 NA
 Tumor location Colon/rectum 1.412 0.297 2.223 0.125 NA
 Tumor size (cm) ≥ 5/< 5 1.692 1.396 2.235 0.039 1.247 0.797 1.571 NS
 Differentiation grade Poor/well + moderate 1.593 1.456 4.153 0.013 1.981 1.446 3.332 0.034
 Local invasion pT3–4/pT1–2 1.588 2.122 4.672 0.009 1.531 1.361 1.861 0.038
 Lymph node metastasis N2/N0 + N1 1.954 1.368 2.661 0.034 1.654 1.182 2.151 0.036
 TNM stage III/I + II 2.181 1.632 3.326 0.018 1.992 1.538 3.034 0.016
 CA19-9 (KU/L) ≥ 37/< 37 1.041 0.406 1.668 0.152 NA
 CEA (ng/mL) ≥ 5/< 5 1.368 0.955 2.174 0.075 NA
 LBX2-AS1 level High/low 3.157 1.823 5.544 0.011 1.675 1.211 2.841 0.022
Disease-free survival
 Gender Male/female 1.334 0.577 1.941 0.373 NA
 Age (years) ≥ 60/< 60 1.231 0.361 1.834 0.286 NA
 Tumor location Colon/rectum 1.279 0.618 1.884 0.823 NA
 Tumor size (cm) ≥ 5/< 5 1.515 1.481 3.346 0.031 0.913 0.745 2.003 NS
 Differentiation grade Poor/well + moderate 1.912 1.717 3.038 0.021 1.957 1.307 3.057 0.045
 Local invasion pT3–4/pT1–2 1.564 1.254 2.885 0.015 1.114 0.977 1.932 NS
 Lymph node metastasis N2/N0 + N1 1.805 1.402 3.366 0.038 1.992 1.334 2.382 0.039
 TNM stage III/I + II 2.155 1.623 3.135 0.028 1.161 0.887 2.112 NS
 CA19-9 (KU/L) ≥ 37/< 37 1.291 0.752 2.684 0.653 NA
 CEA (ng/mL) ≥ 5/< 5 1.317 0.802 2.793 0.438 NA
 LBX2–AS1 level High/low 0.738 0.302 1.543 0.328 NA
  1. HR hazard ratio, 95% CI 95% confidence interval